HAMBURG, Germany and OXFORD, England, October 9 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) is going to hold an R&D Update in London on Tuesday 16 October 2007 at 13.00 pm BST (14.00 pm CET, 08.00 am US time East Coast) which will be broadcast live on the internet.
Jorn Aldag, (President & Chief Executive Officer), Dr John Kemp, (Chief Research & Development Officer) and Dr Tim Tasker, (EVP Clinical Development) will provide an update on the status and development plans for Evotec's Clinical Programs and Discovery Projects. In addition, we are delighted to announce that Dr Michael G Kelly, (SVP Research & Development) at Renovis, will present the Renovis Pipeline Programs.
To join the audio webcast and to access the presentation slides you will find a link on our home page http://www.evotec.com shortly before the event.
For those who prefer to listen to the presentation via phone, please dial:
From Europe: +49(0)69-5007-1308 (Germany)
From the US: +1-718-354-1388
Pass Code: 2793143
The on-demand version of the webcast will be available on our website: http://www.evotec.com - Investors - Webcasts.
About Evotec AG
Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programmes and through research collaborations, the Company is generating the highest quality research results to its partners in the pharmaceutical and biotechnology industries.
In proprietary projects, Evotec specialises in finding new treatments
for diseases of the Central Nervous System. Evotec has three programmes in
clinical development: EVT 201, a partial positive allosteric modulator
(pPAM) of the GABAA receptor complex for the treatment of insomnia, EVT
101, a subtype selective NMDA receptor antagonist fo
|SOURCE Evotec AG|
Copyright©2007 PR Newswire.
All rights reserved